ID   Tm87-16
AC   CVCL_8001
SY   TM87-16; TM 87-16; TM87; TM
DR   BioSample; SAMN10989624
DR   Cell_Model_Passport; SIDM01887
DR   Cosmic; 801769
DR   Cosmic; 802049
DR   Cosmic; 802247
DR   Cosmic; 1063887
DR   Cosmic; 2144782
DR   DepMap; ACH-000172
DR   GEO; GSM3145739
DR   PharmacoDB; TM8716_1599_2019
DR   TOKU-E; 4151
DR   Wikidata; Q54972667
RX   PubMed=1747867;
RX   PubMed=8385567;
RX   PubMed=8818656;
RX   PubMed=9559292;
RX   PubMed=9671307;
RX   PubMed=9920784;
RX   PubMed=10397258;
RX   PubMed=10602515;
RX   PubMed=11557780;
RX   PubMed=11921280;
RX   PubMed=12210830;
RX   PubMed=16557275;
RX   PubMed=24418192;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 45 hours (PubMed=1747867).
CC   Karyotypic information: 46,XY,t(11;22)(p15.5;q11.23) (PubMed=1747867).
CC   Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=9671307; PubMed=10602515; PubMed=11921280).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C6586; Extrarenal rhabdoid tumor
DI   ORDO; Orphanet_69077; Rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1Y9M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 21
//
RX   PubMed=1747867; DOI=10.1016/0165-4608(91)90359-3;
RA   Karnes P.S., Tran T.N., Cui M.-Y., Bogenmann E., Shimada H., Ying K.-L.;
RT   "Establishment of a rhabdoid tumor cell line with a specific
RT   chromosomal abnormality, 46,XY,t(11;22)(p15.5;q11.23).";
RL   Cancer Genet. Cytogenet. 56:31-38(1991).
//
RX   PubMed=8385567; DOI=10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D;
RA   Ota S., Crabbe D.C.G., Tran T.N., Triche T.J., Shimada H.;
RT   "Malignant rhabdoid tumor. A study with two established cell lines.";
RL   Cancer 71:2862-2872(1993).
//
RX   PubMed=8818656; DOI=10.1002/(SICI)1098-2264(199606)16:2<94::AID-GCC3>3.0.CO;2-Y;
RA   Biegel J.A., Allen C.S., Kawasaki K., Shimizu N., Budarf M.L.,
RA   Bell C.J.;
RT   "Narrowing the critical region for a rhabdoid tumor locus in 22q11.";
RL   Genes Chromosomes Cancer 16:94-105(1996).
//
RX   PubMed=9559292; DOI=10.1097/00019606-199712000-00004;
RA   Suzuki A., Ohta S., Shimada M.;
RT   "Gene expression of malignant rhabdoid tumor cell lines by reverse
RT   transcriptase-polymerase chain reaction.";
RL   Diagn. Mol. Pathol. 6:326-332(1997).
//
RX   PubMed=9671307; DOI=10.1038/28212;
RA   Versteege I., Sevenet N., Lange J., Rousseau-Merck M.-F., Ambros P.F.,
RA   Handgretinger R., Aurias A., Delattre O.;
RT   "Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.";
RL   Nature 394:203-206(1998).
//
RX   PubMed=9920784; DOI=10.1006/bbrc.1998.9968;
RA   Mori T., Fukuda Y., Kuroda H., Matsumura T., Ota S., Sugimoto T.,
RA   Nakamura Y., Inazawa J.;
RT   "Cloning and characterization of a novel Rab-family gene, Rab36,
RT   within the region at 22q11.2 that is homozygously deleted in malignant
RT   rhabdoid tumors.";
RL   Biochem. Biophys. Res. Commun. 254:594-600(1999).
//
RX   PubMed=10397258;
RA   Rousseau-Merck M.-F., Versteege I., Legrand I., Couturier J.,
RA   Mairal A., Delattre O., Aurias A.;
RT   "hSNF5/INI1 inactivation is mainly associated with homozygous
RT   deletions and mitotic recombinations in rhabdoid tumors.";
RL   Cancer Res. 59:3152-3156(1999).
//
RX   PubMed=10602515; DOI=10.1038/sj.onc.1203168;
RA   DeCristofaro M.F., Betz B.L., Wang W.-D., Weissman B.E.;
RT   "Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and
RT   primary rhabdomyosarcomas but not Wilms' tumors.";
RL   Oncogene 18:7559-7565(1999).
//
RX   PubMed=11557780; DOI=10.1038/modpathol.3880401;
RA   Itakura E., Tamiya S., Morita K., Shiratsuchi H., Kinoshita Y.,
RA   Oshiro Y., Oda Y., Ohta S., Furue M., Tsuneyoshi M.;
RT   "Subcellular distribution of cytokeratin and vimentin in malignant
RT   rhabdoid tumor: three-dimensional imaging with confocal laser scanning
RT   microscopy and double immunofluorescence.";
RL   Mod. Pathol. 14:854-861(2001).
//
RX   PubMed=11921280; DOI=10.1002/gcc.10052;
RA   Uno K., Takita J., Yokomori K., Tanaka Y., Ohta S., Shimada H.,
RA   Gilles F.H., Sugita K., Abe S., Sako M., Hashizume K., Hayashi Y.;
RT   "Aberrations of the hSNF5/INI1 gene are restricted to malignant
RT   rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric
RT   solid tumors.";
RL   Genes Chromosomes Cancer 34:33-41(2002).
//
RX   PubMed=12210830; DOI=10.1002/jnr.10330;
RA   Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.;
RT   "Malignant rhabdoid tumor shows incomplete neural characteristics as
RT   revealed by expression of SNARE complex.";
RL   J. Neurosci. Res. 69:642-652(2002).
//
RX   PubMed=16557275; DOI=10.1038/modpathol.3800599;
RA   Izumi T., Oda Y., Hasegawa T., Nakanishi Y., Iwasaki H., Sonobe H.,
RA   Goto H., Kusakabe H., Takahira T., Kobayashi C., Kawaguchi K.-i.,
RA   Saito T., Yamamoto H., Tamiya S., Iwamoto Y., Tsuneyoshi M.;
RT   "Prognostic significance of dysadherin expression in epithelioid
RT   sarcoma and its diagnostic utility in distinguishing epithelioid
RT   sarcoma from malignant rhabdoid tumor.";
RL   Mod. Pathol. 19:820-831(2006).
//
RX   PubMed=24418192; DOI=10.1111/cas.12352;
RA   Takita J., Chen Y.-Y., Kato M., Ohki K., Sato Y., Ohta S., Sugita K.,
RA   Nishimura R., Hoshino N., Seki M., Sanada M., Oka A., Hayashi Y.,
RA   Ogawa S.;
RT   "Genome-wide approach to identify second gene targets for malignant
RT   rhabdoid tumors using high-density oligonucleotide microarrays.";
RL   Cancer Sci. 105:258-264(2014).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//